Abstract:Abstract BACKGROUND: Immune checkpoint inhibitors (ICIs) have marked therapeutic effects in many cancer patients. This is not the case for the large majority (~85%) of colorectal cancers (CRC), i.e. those classified as microsatellite stable (MSS) tumors. Cancers that do not respond to immunotherapies, such as this predominant CRC form, have a T cell non-infiltrated phenotype and are known as “cold” tumours. They are poorly immunogenic, as opposed to ICI-responsive “hot” tumours that are associated with high T cell infiltration. A typical immunosuppressive mechanism used by tumors is the production of prostaglandin E2 (PGE2), which binds four EP receptor subtypes on tumor and immune cells to promote tumor survival. The EP4 receptor plays a major role in PGE2-induced immunosuppression. CR6086 is a clinical stage EP4 receptor antagonist acting as a targeted immunomodulator. This study tested the hypothesis that the EP4 antagonist CR6086 could turn cold into hot tumors, favoring the response to ICI therapy. METHODS: We investigated the efficacy of combining CR6086 with an ICI (i.e. anti-mouse PD-1 (CD279), clone RMP1-14 [mAb]) in a syngeneic model of CRC resistant to ICI therapy. CT26 colon carcinoma cells (1 × 106) were inoculated subcutaneously in the right flank of female BALB/c mice. Treatments started on day 7 post-inoculation, when all tumors were within the target volume range of 50-100 mm3. CR6086 (30 mg/kg) was administered orally once daily for 14 days (QDx14); anti-PD-1 mAb (150 μg/mouse) was administered intraperitoneally on days 7, 10, 14 and 17. RESULTS: The combination of CR6086 and anti-PD-1 significantly decreased tumor growth vs vehicle-treated mice (mean tumor volume: 721±166 mm3 vs 1457±219 mm3; P&lt;0.05, Two-way RM ANOVA followed by Dunnett's test, n=11/group), as measured after 14 days of treatment. The anti-PD-1 alone did not affect tumor progression, similarly to CR6086 monotherapy. RT-PCR analysis on tumor tissues showed that combined treatment increased (≥2-fold change) the gene expression of key factors for lymphocyte recruitment and activation. They include specific chemokines (CCL4, CCL5, CXCL10) responsible for increased T cell and dendritic cell infiltrate; CD8α, a major indicator for the presence of cytotoxic T lymphocytes; the antigen processing marker H2-Eb1s; INFγ, a T cell activation factor; TNFα, a cytokine produced by M1 macrophages and involved in tumor cell death; PD-L1, a prognostic biomarker with predictive value for the response of patients under anti-PD-1 therapy. These findings on gene expression are well reflected at the cellular level, because combined treatment increased general and T cell infiltrate, as assessed by haematoxylin/eosin staining and CD3+ immunohistochemistry. Conversely, the combination of CR6086 and anti-PD-1 reduced the gene expression of MMP-9, a matrix metalloproteinase involved in tumor growth, invasion, metastasis, extracellular matrix remodeling, and angiogenesis. CONCLUSION: These results suggest that the EP4 receptor antagonist CR6086 may turn a cold MSS murine colorectal cancer, non-responsive to ICI treatment, into a hot tumor responsive to ICIs. Citation Format: Gianfranco Caselli, Flora Ferrari, Tiziana Piepoli, Adriana Grotti, Rosanna Cavagnoli, Giuseppe M. Montagna, Pierpaolo Romanelli, Albino Bonazzi, Marco Lanza, Camilla Recordati, Lucio C. Rovati. Combination of the EP4 antagonist CR6086 and anti-PD-1 monoclonal antibody inhibits tumor growth in a microsatellite stable colorectal cancer in mice [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 2208.

Abstract 2208: Combination of the EP4 antagonist CR6086 and anti-PD-1 monoclonal antibody inhibits tumor growth in a microsatellite stable colorectal cancer in mice

Intratumoral Injection of Interferon Gamma Promotes the Efficacy of Anti-Pd1 Treatment in Colorectal Cancer

Abstract 4166: Small-molecule inhibition of glycogen synthase kinase-3 (GSK-3) increases the efficacy of anti-PD-L1 therapy in a murine model of microsatellite stable colorectal cancer (CRC); Therapeutic response correlates with T cell ratios and serum cytokine profiles in mice

Abstract 4065: Entinostat synergizes with the IL-15 superagonist N-803 and anti-PD-1 to engage cDC1 and stem-like TCF-1+ CD8+ T and NK cells to overcome colorectal tumors refractory to anti-PD-1 therapy

Abstract 4044: Potentiated antitumor activity of poly-γ-glutamic acid combined with anti PD-L1 blockade on murine models of colorectal cancer

Abstract 4049: The beta-carboline Harmine sensitives microsatellite stable colorectal cancer mouse model to anti-PD-1 through upregulating MHC-I dependent antigen presentation machinery and improving the infiltration of CD8 T cells into the tumor microenvironment

Abstract 4026: The combination of DLL4/VEGF-a blockade and immunomodulation can eliminate MHC class I negative tumors in mice

Abstract 5140: Combined administration of poly(I:C) and resiquimod triggers effective antitumoral response in mouse models of pancreatic adenocarcinoma

Abstract 3535: Simultaneous inhibition of Axl and MerTK enhances anti-PDL1 efficacy and creates a pro-inflammatory tumor immune microenvironment in head and neck cancer

Combined inhibition of CXCL12 and PD-1 in MSS colorectal and pancreatic cancer: modulation of the microenvironment and clinical effects

Abstract 3917: A CXCR4 partial agonist TFF2-MSA improves anti-PD-1 immunotherapy in advanced gastric cancer by selectively targeting PMN-MDSC

Abstract 1189: Modulation of the MSS and MSI colorectal cancer immune microenvironment with FOLFOX and FOLFIRI -/+ anti-PD-1 immunotherapy

Reprogramming Immunosuppressive Myeloid Cells Facilitates Immunotherapy for Colorectal Cancer.

Abstract 1072: Combination of 5-Fluorouracil or ONC212 plus KRAS G12D inhibitor MRTX1133 against colorectal and pancreatic cancer cells results in immune-stimulatory cytokine patterns and unexpected synergies independent of G12D mutation

Neutrophil Extracellular Traps Blockade in Combination with PD-1 Inhibition in Treatment of Colorectal Cancer Metastasis.

Abstract 779: A phase I study of BI 754111, an anti-LAG-3 monoclonal antibody (mAb), in combination with BI 754091, an anti-PD-1 mAb: Biomarker analyses from the microsatellite stable metastatic colorectal cancer (MSS mCRC) cohort

Abstract 2721: Sustained delivery of low-dose anti-CTLA-4 by genetically engineered encapsulated cells to the tumor microenvironment drives tumor response and prolongs survival in a colorectal cancer model

Abstract 2713: Novel anti-PD-L1-IL-15 diabody immunocytokine in combination with radiation therapy improves response rates in immune-resistant murine head and neck cancer

Abstract 5515: Combination of recombinant murine IL-12 and anti-PD-1 induced synergistic anti-tumor response

Abstract 578: Prediction of PD-1 treatment outcome in mismatch repair deficient metastatic colorectal cancer using a multi-omic approach

Abstract 2485: A combined mregDC and Treg signature associates with antitumor efficacy of CCR4 antagonist tivumecirnon FLX475